Today we’re talking to Stephane Doyen, Co-Founder, Director & Chief Data Scientist of Omniscient Neurotechnology; and we discuss how advanced personalized brain mapping technology is changing the game in neuroscience, how Omniscient is leveraging AI to create these maps, and the impact these detailed brain maps are having on patients, doctors, and researchers. 

All of this right here, right now, on the Modern CTO Podcast! 

Check out more of Stephane and Omniscient at https://www.o8t.com/

About Stephane Doyen:

A continual innovator, Stephane Doyen, PhD. MBA, has bridged the gap between science and entrepreneurism. With a PhD in Neuroscience and over 20 publications covering topics from computational methods for analyzing the brain to social psychology, Stephane co-founded an enhanced machine learning brain-mapping company, Omniscient Neurotechnology, to help medical professionals utilize complex brain network data to deliver enhanced patient care. The start-up has been valued at over AUD400M and Stephane is passionate about growing and supporting the organization as Chief Data Scientist and Director. 

Prior to his entrepreneurial venture, he led the delivery of enterprise-grade analytics-based solutions for Fortune 500 organizations such as Oliver Wyman Labs. With his eye on continual innovation, he owns 43 patents and coded Omniscient’s core algorithms: the Structural Connectivity Atlas (SCA) and the Anomaly detector for functional brain scans.

Stephane is passionate about investing in data literacy accessibility, volunteering his time at DataKind, and establishing a partnership with Ishango, a program focused on funding fellows to support Omniscient’s curated data projects, including a key project which involved data analyses from patients living with schizophrenia.

In his free time, Stephane enjoys piloting planes and drones as well as spurring his creative side as a photographer. He speaks fluent French & English.

About Omniscient:

We create enterprise-grade clinical and research solutions applicable to a variety of brain-related disorders, including depression, chronic pain, cancer, bipolar disorder, Alzheimer’s, dementia, and PTSD, with the goal of bringing predictive analytics to the world faster.

We are a data company and aim to radically change the care of patients with brain disease by turning loose Machine learning/AI and big data to actually provide useful information to doctors. This involves both facilitating research, and providing high-quality data-based guidance to clinicians.